Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | The value of treating MGUS and smoldering myeloma patients with novel immunotherapies

Irene Ghobrial • 12 May 2022
COMy 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma Antibodies CAR-T

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, briefly explains the importance of using the best available drugs at an earlier stage instead of waiting until disease progression. Dr Ghobrial also highlights the excitement around immunotherapies, including CAR-T therapy and antibodies, for the treatment of patients with smoldering myeloma and monoclonal gammopathy of undetermined significance (MGUS). This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Irene Ghobrial

0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
Early interception in SMM & novel agents being explored
Irene Ghobrial et al. • 25 Mar 2024
1:19
Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Irene Ghobrial • 11 Dec 2023

Related Videos

3:07
Developing guidelines for the management of infections following treatment with bispecifics
Muhammad Bilal Abid • 23 Jul 2024
Day 1 highlights: imetelstat in MF, challenges with MPN/MDS overlap syndromes & future outlooks
Claire Harrison et al. • 19 Jul 2024
2:55
The discovery of pathogenic germline variants in patients with myeloma
Samir Parekh • 2 Jun 2024
1:25
Predictors and outcomes of extramedullary disease in multiple myeloma
Saurabh Zanwar • 3 Jun 2024
The content of VJHemOnc is intended for healthcare professionals